TY  - JOUR
T1  - Synergistic Effect of Combined Etodolac Plus 5-Fluorouracil in Human Hepatoma Therapy--an <I>In vitro</I> Evaluation by Cell Lines HepG2, HA22T and KELFIB
AU - , Chiu Lan Hsieh AU - , Chiung-Huei Peng AU - , George T. Hsiao AU - , Hui Er Wang AU - , Wan-Shen Ko AU - , Robert Y. Peng 
JO  - Research Journal of Biological Sciences
VL  - 2
IS  - 3
SP  - 268
EP  - 279
PY  - 2007
DA  - 2001/08/19
SN  - 1815-8846
DO  - rjbsci.2007.268.279
UR  - https://makhillpublications.co/view-article.php?doi=rjbsci.2007.268.279
KW  - Hepatoma
KW  -COX-2 inhibitor etodolac
KW  -5-FU
KW  -chemotherapy
AB  - Hepatocellular Cancer Cell (HCC) lines HepG2, HA22T and KEL FIB were used to test the therapeutic effect of different combined protocols for etodolac plus 5-FU: 1). the selective COX 2 inhibitor etodolac alone at 0.0~0.16 µg µL <SUP>1</SUP>; 2). 5-FU alone at 0.0~1.25 µg mL <SUP>1</SUP>; 3). etodolac (0.31 µg µL <SUP>1</SUP>) plus 5-FU (1.25 µg mL <SUP>1</SUP>) in a simultaneous-, or an alternative sequential protocol. Cell viability was measured using MTT assay and flow cytometric analysis. An inverse dose dependent survival rate was observed for both drugs, while the apoptotic data of the three HCC cell lines have favored the simultaneous administration of etodolac plus 5-FU, which revealed to be more effective than administering etodolac or 5-FU alone. We conclude that in view of the therapeutic efficacy with a minimized cytotoxicity, a simultaneous administration of etodolac plus 5-FU, each at much more reduced dosages than usually prescribed alone, could be strongly recommended for treatment of HCC.
ER  -